Ose Pharma International SA (OSE)

Paris
Currency in EUR
6.69
+0.01(+0.15%)
Closed
OSE Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
6.656.76
52 wk Range
3.1211.58
Key Statistics
Edit
Prev. Close
6.68
Open
6.69
Day's Range
6.65-6.76
52 wk Range
3.12-11.58
Volume
43.19K
Average Volume (3m)
160.57K
1-Year Change
87.92%
Book Value / Share
3.74
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OSE Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
12.64
Upside
+88.94%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Ose Pharma International SA Company Profile

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren’s Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.

Compare OSE to Peers and Sector

Metrics to compare
OSE
Peers
Sector
Relationship
P/E Ratio
3.2x−2.7x−0.6x
PEG Ratio
0.01−0.110.00
Price/Book
1.8x1.4x2.6x
Price / LTM Sales
1.8x15.1x3.1x
Upside (Analyst Target)
94.3%241.9%53.0%
Fair Value Upside
Unlock12.7%8.0%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12.64

(+88.94% Upside)

Earnings

Latest Release
May 02, 2023
EPS / Forecast
-0.85 / --
Revenue / Forecast
2.26M / --
EPS Revisions
Last 90 days

People Also Watch

4.64
CATGR
-4.72%
0.0285
ALEUP
0.00%
1.44
BGBN
+2.86%
117.60
ESSF
-0.34%
0.390
ALGAE
0.00%

FAQ

What Is the Ose Pharma International SA (OSE) Stock Price Today?

The Ose Pharma International SA stock price today is 6.69

What Stock Exchange Does Ose Pharma International SA Trade On?

Ose Pharma International SA is listed and trades on the Paris stock exchange.

What Is the Stock Symbol for Ose Pharma International SA?

The stock symbol for Ose Pharma International SA is "OSE."

What Is the Ose Pharma International SA Market Cap?

As of today, Ose Pharma International SA market cap is 146.33M.

What is Ose Pharma International SA Earnings Per Share?

The Ose Pharma International SA EPS is 2.18.

From a Technical Analysis Perspective, Is OSE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.